MCL1 and non-small cell lung carcinoma: While reverse resistance can help to explain why there are so few genes in common when cisplatin and gemcitibane (MRP5, MCL1, MVP) and cisplatin and docetaxel (GSTπ, MRP8, FPGS, P53, DPD, IAP2) are used together as opposed to separately (Table 6), the number of extra genes correlated when cisplatin is used in combination with gemcitabine (n = 19) and docetaxel (n = 14) indicates that there may be still unknown linkages and pathways between NSCLC-related genes that need further exploration.